hotspot -WSS

hotspot

author：focus 2025-08-11 08:00:28 - browse：5673

An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA agreed that the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi) outperformed placebo in trials. It is expected to receive full approval by July 6.

But this may not necessarily be purely good news.

On the latest episode of the “First Opinion Podcast,” physician and professor Jason Karlawish argues that lecanemab and other promising new drugs, such as donanemab, will introduce complicated issues into the field of Alzheimer’s care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

“Dr. Karlawish’s dream of reason would be … a training module for physicians to learn the key things they need to learn and then self-assess their comfort with the drug,” Karlawish said. “But that’s Karlawish’s dream of reason in a world that seems increasingly less reasonable sometimes.”

Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine. The conversation is based off his recent First Opinion, “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： 3 hurdles to bringing medical devices to the U.S. market

WSS

Do masks work? RCTs can't tell us

Trump Jan. 6 attorney John Lauro is ex

Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

Mississippi candidates for statewide offices square off in party primaries

Death of patient in Alzheimer’s trial raises question of possible risks

WATCH: Why do fingernails fall off when they're damaged?

leisure time

hotspot

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

Bursting ice dam in Alaska highlights risks of glacial flooding around the globe

Anesthesiologist group: stop taking Ozempic before surgery

Paxlovid study fails to answer questions over benefit for broader groups

Activists slam private health insurers over coverage restrictions

New guidelines on severe brain injury complicate already difficult decisions

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Trump demands the U.S. pay no more for drugs than other countries … again

Tesla CFO Zachary Kirkhorn steps down, but will remain with company through year's end

focus

'The Exorcist' director William Friedkin dead at 87

Moderna hits safety problems in bold bid to reinvent medicine

Nearly a dozen Russian and Chinese ships now moving away from Alaska, officials say

Bursting ice dam in Alaska highlights risks of glacial flooding around the globe

DeSantis and Newsom agree to Sean Hannity debate, then disagree on the rules

Disclosing genetic information: not as worrisome as once feared

leisure time

explore

entertainment

focus